CLRB Cellectar Biosciences, Inc.
Price Chart
Executive Summary
Cellectar Biosciences announced positive Phase 2 CLOVER WaM data at ASCO for iopofosine I 131 in post-BTKi Waldenström macroglobulinemia patients, showing a 79.2% major response rate and median duration of response exceeding 16 months. The company plans to pursue accelerated approval and initiate a Phase 3 confirmatory trial in Q4 2026. For a $25M market cap company, this data is a significant catalyst but the path to approval remains uncertain.
Actionable Insight
The strong efficacy and durability data in a difficult-to-treat population support a potential accelerated approval pathway. Traders should watch for FDA interactions and the initiation of the Phase 3 trial in Q4 2026 as key catalysts. Given the small market cap, positive regulatory updates could drive outsized moves, but clinical and regulatory risks remain high.
Key Facts
- 79.2% major response rate (partial response or better) in 24 post-BTKi WM patients
- Median duration of response of 16 months (range: 7.3–25.4 months)
- 100% clinical benefit rate and 87.5% overall response rate
- 20% of patients exceeded 30 months duration of response
- Cytopenias were the only Grade 3+ adverse event; manageable toxicity profile
- Company plans to pursue accelerated approval in the U.S. and initiate a Phase 3 confirmatory study in Q4 2026
- Iopofosine I 131 has FDA Breakthrough Therapy, Orphan Drug, Rare Pediatric Disease, and Fast Track designations
Financial Impact
No financial figures provided; market cap ~$25M; positive data could drive significant upside if accelerated approval pathway is successful
Risk Factors
- Accelerated approval not guaranteed; FDA may require additional data
- Phase 3 confirmatory trial may fail or be delayed
- Company may need to raise capital to fund Phase 3 and operations
- Competing therapies for WM could limit commercial potential
- Small market cap and low liquidity increase volatility risk
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304338 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
5d ago
|
Press Release
| $2.97 $2.74 | ▼ −7.74% | ▼ −7.89% | $2.59 (−12.79%) |
|
May 29, 2026
8d ago
|
S-1/A
| $3.14 $2.97 | ▲ +5.41% | ▲ +5.69% | $2.59 (+17.52%) |
|
May 28, 2026
9d ago
|
DEFA14A
| $3.14 $2.97 | ▼ −5.41% | ▼ −5.67% | $2.59 (−17.52%) |
|
May 19, 2026
18d ago
|
S-1
| $3.17 $3.17 | · 0.00% | ▲ +0.19% | $2.59 (+18.30%) |
|
May 14, 2026
23d ago
|
8-K
| $3.20 $3.09 | ▼ −3.44% | ▼ −2.21% | $2.59 (−19.06%) |
|
May 14, 2026
23d ago
|
Press Release
| $3.20 $3.09 | ▼ −3.44% | ▼ −2.21% | $2.59 (−19.06%) |
|
May 11, 2026
26d ago
|
Press Release
| $3.06 $2.92 | ▼ −4.58% | ▼ −4.44% | $2.59 (−15.36%) |
|
May 8, 2026
29d ago
|
8-K
| $3.10 $3.06 | ▲ +1.29% | ▲ +1.52% | $2.59 (+16.45%) |
|
May 7, 2026
4w ago
|
Insider Cluster
| $3.30 $3.10 | ▲ +6.06% | ▲ +6.89% | $2.59 (+21.52%) |
|
May 6, 2026
4w ago
|
424B5
| $3.53 $3.30 | ▲ +6.52% | ▲ +6.18% | $2.59 (+26.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access